gastric cancer
Conditions
Interventions
High risk group 1:New quadruple therapy (PPI, bismuth, tetracycline and furazolidone)
High risk group 2:Classic first-line therapy (PPI, bismuth, amoxicillin and clarithromycin)
Low risk group:no intervention
Sponsors
General Hospital, Tianjin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) aged 18 to 85 years, male or female;(2) positive for Hp infection was confirmed by 13C urea breath test;(3) those who have undergone gastroscopy examination;(4) agreed to participate in this study and conduct Hp eradication, endoscopic and pathological examinations and follow-up, and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) those who have received successful Hp eradication therapy; (2) pregnant and lactating patients; (3) patients have other severe diseases that may affect the results of this study, such as severe liver disease, cardiovascular disease, respiratory disease, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastrin-17;Pepsinogen ?/ ?;Susceptibility loci;Helicobacter pylori virulence factor antibody; | — |
Countries
China
Contacts
Public ContactKui Jiang
General Hospital, Tianjin Medical University
Outcome results
None listed